SCHEMBL29329652

SCHEMBL29329652

NCC(CN1C(=O)C=C(Br)C1=O)CN1C(=O)C=C(Br)C1O

nearest known ligand 0.35

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
RGS4 P49798 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22153145 0.83 RGS4 (0.46) RGS4
SCHEMBL4848834 0.64 RGS4 (0.45) RGS4
SCHEMBL22152325 0.59 RGS4 (0.44) RGS4
SCHEMBL18925542 0.58 RGS4 (0.42) RGS4
SCHEMBL3470129 0.58 RGS4 (0.53) RGS4
SCHEMBL4847030 0.58 RGS4 (0.53) RGS4
SCHEMBL20320712 0.56
SCHEMBL20574477 0.56 RGS4 (0.50) RGS4
SCHEMBL21610408 0.55
SCHEMBL16307837 0.54 RGS4 (0.49) RGS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3868409-B1 THIOPHENOL-MALEIMIDE AND BROM-MALEIMIDE DERIVATIVES AS LINKER FOR ANTIBODY-DRUG CONJUGATES (ADC) FOR TREATING TUMORS REMEGEN CO LTD (CN) 2024-07-17 EP disclosed